Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin in Stage IIIb and IV Non Small Lung Cancer: A phase III Randomized Trial

Warning

This publication doesn't include Faculty of Arts. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	ZATLOUKAL Petr PETRUZELKA Luboš ZEMANOVÁ Milada KOLEK Vítězslav SKŘIČKOVÁ Jana PEŠEK Miloš SIXTOVÁ Dimka ROUBEC Martin HAVEL Libor PRUŠA Petr
Year of publication	2003
Type	Article in Periodical
Magazine / Source	Lung Cancer
MU Faculty or unit	Faculty of Medicine
Citation
Field	Pneumology
Keywords	Non Small Cell Lung Cancer; Stage IIIb and IV; Gemcitabine; Cisplatin; Carboplatin
Description	The ranomized, muticenter, phase III trial was conducted to compare the tolerability of gemcitabine plus cisplatine (GP) vs. gemcitabine plus carpolatin (GC). The enroled patients in GC and GP arm were balanced for demographic and disease characteristics. Both GP and GC are ffective options, the GC arm offering the advantage to pts unable to receive cisplatin.
Related projects:	Environment - carcinogenesis - oncology